Coherus Oncology: Revolutionizing Cancer Treatment with Innovative Strategies
Coherus Oncology, Inc. recently concluded its fourth quarter and 2025 year-end earnings conference call, providing insight into the company's transformative journey to become a leading innovative oncology company.
Under the strategic leadership of Chief Executive Officer Denny Lanfear, Coherus has successfully completed its transformation by divesting its biosimilar franchise, reducing debt, and refocusing on cancer treatment. This strategic shift was initiated in September 2023 with the acquisition of Surface Oncology, a move that brought promising assets like tagmokitug and Casdozokitug into the company's portfolio.
The acquisition not only expanded Coherus' product offerings but also allowed the company to initiate an elegantly efficient clinical development program. This initiative has enabled the potential for registration trials in 2027, further solidifying the company's commitment to innovative cancer treatment.
Another significant milestone achieved by Coherus is the launch of its first innovative oncology commercial product, LOQTORZI, in 2024. As a next-gen PD one inhibitor, LOQTORZI holds a unique position as the only FDA-approved product for recurrent, locally advanced or metastatic Nasopharyngeal Carcinoma (NPC) in the U.S., boasting an addressable market of $250 million.
LOQTORZI has shown remarkable growth, with sales more than doubling in 2025 compared to the previous year. This success is attributed to the product's reliability and its ability to generate revenue while supporting Coherus' operations. The company expects LOQTORZI to achieve peak market share sometime in 2028, corresponding to $175 million in annualized revenues or about 70% market share of the total $250 million market.
While $175 million may appear modest compared to other revenue projections, it's crucial for Coherus as it covers the company's core burn and overall headcount expenses. Moreover, once LOQTORZI achieves around $15 or $16 million a quarter in sales, the commercial effort will have paid for itself and start contributing to covering the company's overall SG&A.
Chief Commercial Officer Sameer Goregaoker elaborated on LOQTORZI's growth trajectory, emphasizing its significance as both a revenue generator and a multiplier. This confidence in LOQTORZI's continued growth is bolstered by its position at the top of the NCCN guidelines for recurrent metastatic NPC.
Coherus Oncology's transformation into an innovative oncology company has been marked by strategic decisions, successful product launches, and promising clinical development programs. The company's commitment to advancing cancer treatment has positioned it as a leader in the industry, with a focus on overcoming immune resistance and improving patient outcomes.
